[CAS NO. 1312547-19-5] Samatasvir

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1312547-19-5]

Catalog

HY-16784

Brand

MCE

CAS

1312547-19-5

DESCRIPTION [1312547-19-5]

Overview

MDL	-
Molecular Weight	885.06
Molecular Formula	C47H48N8O6S2
SMILES	O=C(OC)N[C@H](C1=CC=CC=C1)C(N2[C@H](C3=NC=C(C4=CC=C(C5=CSC6=C5SC=C6C7=CC=C8N=C([C@H]9N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC9)NC8=C7)C=C4)N3)CCC2)=O

For research use only. We do not sell to patients.

Summary

Samatasvir (IDX71) is a potent, orally active NS5A inhibitor of HCV replication. Samatasvir is effective and selective against infectious HCV and replicons, with EC ₅₀ s falling within a tight range of 2 to 24 pM in genotype 1 through 5 replicons ^[1] .

In Vitro

Samatasvir (IDX719) retains full activity in the presence of HIV and hepatitis B virus (HBV) antivirals and is not cross-resistant with HCV protease, nucleotide, and nonnucleoside polymerase inhibitor classes ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01508156	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	January 2012	Phase 1\|Phase 2
NCT01813513	Merck Sharp & Dohme LLC	Chronic Hepatitis C Infection	January 2013	Phase 1
NCT01335607	Merck Sharp & Dohme LLC	Hepatitis C	April 2011	Phase 1
NCT01919125	Merck Sharp & Dohme LLC	Hepatitis C, Chronic	August 2013	Phase 1
NCT01813552	Merck Sharp & Dohme LLC	Chronic Hepatitis C Infection	February 2013	Phase 1
NCT01907724	Merck Sharp & Dohme LLC\|Janssen Research & Development, LLC	Hepatitis C, Chronic	May 2013	Phase 1
NCT01852604	Merck Sharp & Dohme LLC\|Janssen Research & Development, LLC	Chronic Hepatitis C Virus	March 2013	Phase 2

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 56.49 mM ; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1299 mL	5.6493 mL	11.2987 mL
5 mM	0.2260 mL	1.1299 mL	2.2597 mL
10 mM	0.1130 mL	0.5649 mL	1.1299 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 2.5 mg/mL (2.82 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: 2.5 mg/mL (2.82 mM); Suspended solution; Need ultrasonic

* All of the co-solvents are available by MCE.

References

[1] Bilello JP, et al. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2014;58(8):4431-4442.

Synonyms

Carbamic acid, N-[(1R)-2-[(2S)-2-[5-[4-[6-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-benzimidazol-6-yl]thieno[3,2-b]thien-3-yl]phenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]-2-oxo-1-phenylethyl]-, methyl ester

Samatasvir

IDX 18719

IDX 719